Adaptive radiotherapy for head and neck cancer patients
Head and neck (HN) cancer is the eighth most common cancer in the UK. The incidence is around 12,400 new cases every year and the incidence rate has increased by a fifth in the past 10 years. According to Cancer Research UK, between 43% and 85% of those HN cancers have radiotherapy as part of their primary cancer treatment. With recent advances in radiotherapy technologies including imaging, treatment planning software and radiation delivery systems, adaptive radiotherapy (ART) has seen increasing research interest, particularly for HN cancer patients.
The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.


